CVAC vs. SLN, PAHC, ORIC, LYEL, PHAR, BCYC, ZYME, NUVB, NRIX, and ANAB
Should you be buying CureVac stock or one of its competitors? The main competitors of CureVac include Silence Therapeutics (SLN), Phibro Animal Health (PAHC), ORIC Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), Pharming Group (PHAR), Bicycle Therapeutics (BCYC), Zymeworks (ZYME), Nuvation Bio (NUVB), Nurix Therapeutics (NRIX), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical preparations" industry.
CureVac (NASDAQ:CVAC) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
CureVac has a beta of 2.51, suggesting that its share price is 151% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.
Silence Therapeutics has a net margin of -131.44% compared to CureVac's net margin of -483.85%. CureVac's return on equity of -41.87% beat Silence Therapeutics' return on equity.
Silence Therapeutics has lower revenue, but higher earnings than CureVac. Silence Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
CureVac currently has a consensus price target of $8.33, indicating a potential upside of 138.78%. Silence Therapeutics has a consensus price target of $57.25, indicating a potential upside of 148.91%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Silence Therapeutics is more favorable than CureVac.
In the previous week, Silence Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 8 mentions for Silence Therapeutics and 2 mentions for CureVac. Silence Therapeutics' average media sentiment score of 0.64 beat CureVac's score of 0.25 indicating that Silence Therapeutics is being referred to more favorably in the news media.
17.3% of CureVac shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 2.2% of CureVac shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Silence Therapeutics received 1 more outperform votes than CureVac when rated by MarketBeat users. Likewise, 71.88% of users gave Silence Therapeutics an outperform vote while only 51.16% of users gave CureVac an outperform vote.
Summary
Silence Therapeutics beats CureVac on 13 of the 18 factors compared between the two stocks.
Get CureVac News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
